Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05087641

A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema

The Pulmair Implantable Artificial Bronchus (IAB) is a device intended for implantation into the diseased bronchi of emphysema patients. The IAB is indicated for bronchoscopic treatment of adults with Chronic Obstructive Pulmonary Disease (COPD)/emphysema to relieve hyperinflation and allow bidirectional ventilation of the affected lobes.

The objective of this trial is to demonstrate a suitable benefit/risk profile to support a subsequent trial of the safety and effectiveness of the IAB to achieve its intended purpose.

The trial will enroll 24 subjects implanted with IAB(s), at no more than three study centers.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Emphysema Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed Informed Consent
  • Diagnosis of COPD/emphysema
  • Age 40 to 75 years
  • Body Mass Index (BMI) less than 30 kg/m2
  • 6-minute walk Distance between 100 meters and 500 meters at baseline exam
  • Stable disease with less than 10 mg prednisone (or equivalent) daily
  • Non-smoking for 4 months prior to screening interview
  • FEV1 between 15% and 50% of predicted value at baseline exam
  • FEV1/Forced Vital Capacity (FVC) < 70%
  • RV > 175%
  • mMRC score ≥ 2

Exclusion criteria

  • Currently participating in another clinical study
  • Women of child-bearing potential
  • More than 2 COPD exacerbation episodes requiring hospitalization in the last year at screening
  • Any COPD exacerbations within 6 weeks of planned intervention
  • Two or more instances of pneumonia episodes in the last year at screening
  • Clinically significant mucus production or chronic bronchitis
  • Myocardial Infarction or unstable / uncontrolled congestive heart failure within 6 months of screening
  • Prior lung transplant, Lung Volume Reduction Surgery (LVRS), bullectomy or lobectomy
  • Clinically significant bronchiectasis
  • Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7 days
  • Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure > 45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram (completed within the last 3 months prior to screening visit)
  • Suspected pulmonary nodule or lung cancer
  • High Resolution Computed Tomography (HRCT) collected per CT scanning protocol within the last 6 months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:
  • Large bullae encompassing greater than 30% of either lung
  • Insufficient landmarks to evaluate the CT study using the software as it is intended
  • All lobes are less than 25% parenchyma diseased (< -950 HU)
  • Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant
  • Total Lung Capacity (TLC) < 100% predicted at screening
  • Diffusing Capacity of Carbon Monoxide (DLCO) < 15% or > 50% of predicted value at screening
  • Partial pressure of carbon dioxide (PaCO2) > 50 mm Hg or Denver scale greater than 55 mm Hg on room air at screening
  • Partial pressure of oxygen (PaO2) < 45 mm Hg or Denver scale less than 30 mm Hg on room air at screening
  • Plasma cotinine level > 13.7 ng/ml or carboxyhemoglobin (arterial or ear lobe capillary) > 2.5% at screening
  • Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study

Treatment and study plan

IAB System

Device

Bronchoscopic implantation of one or multiple IABs

Primary outcomes

  1. Safety - Incidence of respiratory serious adverse events (SAEs)

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    The primary endpoint is the occurrence of respiratory SAEs:

    • Acute asthma/bronchospasm requiring intensive/critical care unit admission
    • Acute COPD exacerbation (is acute onset, life-threatening, requires hospitalization)
    • Airway injury from IAB placement/migration/airway stenosis requiring surgical intervention
    • Death from procedure/IAB
    • Massive hemoptysis (est. >100 ml in 24hr requiring transfusion, surgery, or arterial embolization) from procedure/IAB
    • Pneumonia in treated lobe requiring hospitaliz., IV antibiotics, IAB removal
    • Pneumonia NOT in treated lobe (is life-threatening, acute onset, requires hospitaliz. & IV antibiotics)
    • Pneumothorax requiring surgery
    • Tension pneumothorax (is life-threatening, acute onset, requires hospitaliz. & treatment)
    • Respiratory failure requiring mechanical ventilatory support >24hr

    A thoracic SAE composite, based on number of subjects experiencing a thoracic SAE, will also be calculated and tabulated.

Secondary outcomes

  1. Safety - Incidence of other serious adverse device effects (SADEs)

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    All other SADEs are a secondary endpoint, made from the accumulation of adverse events (AEs) to be recorded as they occur regardless of the follow-up schedule.

  2. Efficacy - Residual Volume (RV), absolute change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Absolute change in Residual Volume (RV)

  3. Efficacy - Residual Volume (RV), percent change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Percent change in RV (% predicted)

  4. Efficacy - Forced Expiratory Volume in one second (FEV1), absolute change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Absolute change in FEV1

  5. Efficacy - Forced Expiratory Volume in one second (FEV1), percentage change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Percentage change in FEV1

  6. Efficacy - Six-Minute Walk Distance (6MWD), absolute change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Absolute change in 6MWD

  7. Efficacy - Six-Minute Walk Distance (6MWD), percent change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Percent change in 6MWD

  8. Efficacy - Modified Medical Research Council (mMRC) dyspnea score, absolute change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Absolute change in mMRC dyspnea score. Scores range from 0-4, with a decrease in score representing improved perception of disability attributable to dyspnea.

  9. Efficacy - St. George's Respiratory Questionnaire (SGRQ) total score, absolute change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Absolute change in SGRQ total score. Scores range from 0-100, with a decrease in score representing overall improvement in health, daily life, and perceived well-being.

  10. Efficacy - St. George's Respiratory Questionnaire (SGRQ), percent change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Percent change in SGRQ

  11. Efficacy - COPD Assessment Test (CAT), absolute change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Absolute changes in CAT. Scores range from 0-40, with a decrease in score representing decreased impact of cough, sputum, dyspnea, and chest tightness on overall health status.

  12. Efficacy - COPD Assessment Test (CAT) Total Score, percent change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Percent change in CAT Total Score

  13. Efficacy - European Quality of Life, 5-Dimensional Test (EQ-5D) Summary Index, absolute change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Absolute change in EQ-5D Summary Index. Index values range from 0-1, with a decrease in index value indicating an improvement in health-related quality of life.

  14. Efficacy - European Quality of Life, 5-Dimensional Test (EQ-5D) Summary Index, percent change

    Time frame: From baseline to 90 days post implant (for endpoint evaluation)

    Percent change in EQ-5D Summary Index

Sponsors and collaborators

Lead sponsor

Pulmair Medical, Inc.

Industry

Registry information

Acronym: IAB-1

Important dates

Study start
2022
Primary completion
2024
Study completion
2027
First posted
Oct 21, 2021
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.